The Alzheimer’s Drug Discovery Foundation (ADDF) and The Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced a USD 5 million research partnership to accelerate development of minimally invasive biomarkers targeting pathologies shared between Alzheimer’s disease and Parkinson’s disease. The collaboration, structured as a pooled funding commitment between the two nonprofit foundations, deploys the ADDF’s Diagnostics Accelerator (DxA) platform alongside MJFF’s Parkinson’s research infrastructure and biosample resources to pursue scalable diagnostic tools capable of detecting co-pathologies across both conditions.
No specific drug or clinical candidate is involved. The partnership is focused exclusively on biomarker discovery and validation, with an emphasis on fluid-based or otherwise minimally invasive detection methods. The individual contribution split between the two foundations was not disclosed, nor were specific milestone structures, territorial terms, or royalty arrangements — none of which apply to this type of nonprofit research collaboration. The USD 5 million represents the full committed research envelope as announced.
The DxA platform, which ADDF operates as its diagnostics-focused funding and scientific infrastructure arm, has previously been deployed to accelerate biomarker programs from early discovery toward clinical utility. Its role in this deal is to provide the funding architecture and translational expertise needed to advance co-pathology biomarker programs — specifically those capable of identifying shared biological features across the Alzheimer’s and Parkinson’s disease boundary. The scientific rationale centers on the recognition that overlapping proteinopathies and neuroinflammatory signatures are clinically relevant across both conditions but currently lack validated, minimally invasive detection methods. No specific biofluid modality or biological target was disclosed in the announced terms.
Both organizations bring established track records in cross-disease biomarker work. MJFF’s C2N Diagnostics partnership, announced in January 2025, deployed blood-based diagnostic tools to investigate biomarker links between Parkinson’s disease, Lewy body dementia, and Alzheimer’s disease through the foundation’s Parkinson’s Progression Markers Initiative cohort — a directly comparable cross-pathology biomarker effort. The ADDF’s DxA licensed its proprietary SpeechDx dataset to Siemens Healthineers in May 2025 for development of speech-based Alzheimer’s biomarkers, marking the first of multiple planned licensees for the platform and demonstrating the DxA’s capacity to generate commercially transferable diagnostic assets. The current ADDF-MJFF collaboration extends both organizations’ cross-disease biomarker strategies into a jointly funded program, which neither foundation had previously pursued together at this scale.
This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/